Neu­ro­crine ex­ecs shrug off a PhII set­back for Tourette syn­drome

Neu­ro­crine was forced to con­cede that its lead drug – al­ready on track at the FDA with an ap­pli­ca­tion for tar­dive dysk­i­ne­sia — just flunked a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.